†Based on the top-selling dietary supplement brands by revenue per the largest U.S. e-commerce marketplace (as of 1/1/2024 - 12/31/2024). About iCRYO Founded in 2015, iCRYO’s mission is to elevate the quality of life of its team members, guests,...
for the treatment of early Alzheimer's disease by the National Medical Products Administration (NMPA) in China. In January 2024, lecanemab was approved for the treatment of Alzheimer's disease (AD) in patients with mild cognitive impairment (MCI)...
trials conducted by Alteogen Biologics in 12 countries, including Europe, South Korea and Japan from June 2022 to February 2024. The comparative clinical evaluation involving 431 wAMD patients demonstrated that EYLUXVI®'s efficacy and safety are...
from a reputed global consulting firm. 2Among the Top 10 Professional Skin Care Brands in the U.S., according to Kline’s 2024 Global Professional Skin Care Series (China, Europe and the U.S.). About Waldencast: Founded by Michel Brousset and Hind...
Sankyo will maintain exclusive rights. Daiichi Sankyo will be solely responsible for manufacturing and supply. In August 2024, the global co-development and co-commercialization agreement was expanded to include gocatamig (MK-6070/DS3280), which...
facility in Bidar, India (Unit IV). The Phase I of PB-11, with a capacity of 110 KL, was inaugurated in December 2024. With the addition of Phase II (~91 KL) in Q1 FY26, the combined capacity of the block now stands at ~200 KL, making it the single...
it from existing therapies. This milestone follows the FDA’s designation of VTB-10 as an Orphan Drug (ODD) in November 2024, enabling VASTHERA to formally begin global clinical development. The program has been supported by national funding from...
parts of the world due to widespread vaccination campaigns, but it continues to circulate in Afghanistan and Pakistan. In 2024, wild poliovirus type 1 (WPV1) transmission rose significantly in Afghanistan. The use of Tropis ID enables site-to-site...
Market: According to Grand View Research, the global obesity therapeutics market is valued at 15.9 billion US dollars in 2024 and is projected to grow to 60.5 billion US dollars by 2030. Currently, therapeutic and safety advantages in the GLP-1...
The Company is developing orticumab for secondary prevention of cardiac events after acute coronary syndrome (ACS). In 2024, Abcentra published promising clinical data from a phase 2a pilot study, which established clinical proof-of activity of...
ophthalmic solution was approved as dry eye drug therapy in the United States and in Canada in May 2023 and September 2024, respectively. About Hengrui Pharma: Jiangsu Hengrui Pharmaceuticals Co., Ltd. (Hengrui Pharma) is an innovative, global...
the development of optimized outpatient care models. Additionally, "Guidelines for the Diagnosis and Treatment of Obesity (2024 Edition)" recommended pharmacotherapy when lifestyle interventions fail to meet weight loss goals. The "Guidelines for...
Bioscience and a meaningful recognition of the outstanding work delivered by our global operations team. Alongside our 2024 Excellence in Client Services and Partnership Award, these accolades highlight our unwavering commitment to serving clients...
2025 would like to welcome all the pharmaceutical professionals and companies to speak at our prestigious Pharma Summit 2024 slated on June 23 - 24, 2025. The Global Pharma Tech Summit 2025 would like to welcome all the pharmaceutical professionals...
were eligible for R-ICE and ASCT, and had received ≥1 prior line of treatment. At the time of data cutoff (December 18, 2024), median follow-up was 11 months (range, 6−15). Among the 31 patients treated with epcoritamab 48 mg + R-ICE, 61 percent...
with a median follow-up for responses of 19 months, the longest DOR was observed at 30.4 months and ongoing as of October 2024. Given the single-arm nature of the TRUST clinical studies, median progression-free survival (PFS) is not provided in the...
designation received for the HADLIMA low-concentration (40 mg/0.8 mL) prefilled syringe and single-dose vial in June 2024.1 With today’s additional interchangeability designations, HADLIMA is now interchangeable with all presentations of the...
associated with septic shock. The product launch adds to the company’s offerings of Epinephrine Injection. In December 2024, Fresenius Kabi introduced the first generic version of Epinephrine, USP, in a 1 mg per mL vial for U.S. customers. “We are...
partnership for the ustekinumab biosimilar covering key global markets. The drug received FDA approval in September 2024 and has been available in the U.S. since March 2025. Otulfi (ustekinumab-aauz) is a human monoclonal antibody that targets the...
platform has shaped the development of immunoregulatory therapeutics like omilancor, NX-13 (acquired by Abbvie in March 2024) and NIM-1324. About NIMML: The NIMML Institute is a 501 (c) (3) non-profit foundation dedicated to combining advanced...
